key: cord-1025696-k8vlgkzg authors: Niculescu, Adelina-Gabriela; Bîrcă, Alexandra Cătălina; Grumezescu, Alexandru Mihai title: New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery date: 2021-12-01 journal: Pharmaceutics DOI: 10.3390/pharmaceutics13122053 sha: 504d3dc64f4b516ff6b1d94d5164c7dac7cc6131 doc_id: 1025696 cord_uid: k8vlgkzg Nucleic acids represent a promising lead for engineering the immune system. However, naked DNA, mRNA, siRNA, and other nucleic acids are prone to enzymatic degradation and face challenges crossing the cell membrane. Therefore, increasing research has been recently focused on developing novel delivery systems that are able to overcome these drawbacks. Particular attention has been drawn to designing lipid and polymer-based nanoparticles that protect nucleic acids and ensure their targeted delivery, controlled release, and enhanced cellular uptake. In this respect, this review aims to present the recent advances in the field, highlighting the possibility of using these nanosystems for therapeutic and prophylactic purposes towards combatting a broad range of infectious, chronic, and genetic disorders. The recent investigation of a multitude of therapeutic nucleic acids (TNAs) has paved the way for developing new treatment strategies for various wounds, infectious diseases, and chronic conditions. TNAs, such as plasmid DNA (pDNA), small interfering (or silencing) RNA (siRNA), self-amplifying RNA (saRNA), microRNA mimics, anti-microRNA oligonucleotides, messenger RNA (mRNA), and antisense oligonucleotides (ASOs), can be employed for creating therapeutics and vaccines that provide a cell-mediated immune response [1] [2] [3] [4] [5] [6] [7] . TNAs have gained increasing scientific interest, especially due to the long-lasting effects they offer in contrast to conventional treatments. Specifically, traditional medication induces temporary effects as it targets proteins instead of the underlying causes. In comparison, TNAs have the potential to produce long-term and even curative effects by gene inhibition, addition, replacement, or editing [2] . However, the direct delivery of nucleic acids has several drawbacks as naked nucleic acids are prone to enzymatic degradation, renal clearance, and poor cellular uptake as they face difficulties in crossing the cell membrane [4, [8] [9] [10] . These challenges are mainly due to TNAs' large molecular weight, negatively charged backbone, and more fragile and immunogenic potential than their oligonucleotide counterparts [6, 11] . Thus, the clinical translation of such treatments is highly dependent on the delivery technologies that must enhance TNAs' stability, protect against extracellular degradation, facilitate cell internalization, and improve target affinity [2, 3, 8] . In this respect, a broad range of delivery systems has been studied. Delivery vehicles such as lipid nanoparticles, polymeric micelles, dendrimers, polymer-based nanoparticles, hydrogels, polyplexes, proteins, and inorganic nanomaterials are under investigation [1, 12] . Out of this plethora of possibilities, lipid nanoparticles are the most clinically In this respect, a broad range of delivery systems has been studied. Delivery vehicles such as lipid nanoparticles, polymeric micelles, dendrimers, polymer-based nanoparticles, hydrogels, polyplexes, proteins, and inorganic nanomaterials are under investigation [1, 12] . Out of this plethora of possibilities, lipid nanoparticles are the most clinically advanced [11, 13, 14] ; however, polymer and polymer-lipid hybrid particles have also recently become important categories of carrier platforms [15] [16] [17] [18] . Moreover, such delivery systems have become highly attractive due to their targeting potential as they can be surface functionalized to allow accumulation and payload release in specific tissues [11, 19, 20] . In this context, this paper aims to provide an overview of the newly developed lipid and polymer-based nanosystems for nucleic acid delivery, emphasizing their importance in combatting various infectious, chronic, and genetic disorders. Lipid nanoparticles (LNPs) have attracted considerable research interest for encapsulating TNAs, especially due to their ionizable lipid presence, which is cationic at a low pH, thus, allowing complexation with negatively charged RNA or DNA [21, 22] . Various generations of lipid nanocarriers have been tackled for TNAs delivery, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and cationic lipid-nucleic acid complexes [23] . A brief history of how lipid-based RNA delivery systems evolved until the date is represented in Figure 1 . [2, 11, 16, 24] , published by Nature Publishing Group, 2021; Elsevier, 2020; Nature Publishing Group, 2021; https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/376/366/safc-lipids-rna-wp7004en-ms.pdf, accessed on 10 October 2021. LNPs have also been extensively studied due to the relatively easy and scalable manufacturing processes they can be obtained through [3] . Specialized manufacturing and control techniques ensure the complex morphology and tailored lipid components and proportions required to create functional and efficient LNP-based delivery systems [11] . Examples of conventional synthesis methods include high-pressure homogenization [2, 11, 16, 24] , published by Nature Publishing Group, 2021; Elsevier, 2020; Nature Publishing Group, 2021; https://www. sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/376/366/safc-lipids-rna-wp7004en-ms.pdf, accessed on 10 October 2021. LNPs have also been extensively studied due to the relatively easy and scalable manufacturing processes they can be obtained through [3] . Specialized manufacturing and control techniques ensure the complex morphology and tailored lipid components and proportions required to create functional and efficient LNP-based delivery systems [11] . Examples of conventional synthesis methods include high-pressure homogenization [25, 26] , solvent emulsification-evaporation [27] , ethanol injection nanoprecipitation [28] , freezedrying [29] , and preformed vesicle method [30] (Figure 2 ). [25, 26] , solvent emulsification-evaporation [27] , ethanol injection nanoprecipitation [28] , freeze-drying [29] , and preformed vesicle method [30] (Figure 2 ). For instance, Gomez-Aguado et al. [27] used the solvent emulsification-evaporation method to develop different solid lipid nanoparticles (SLNs) that combine cationic and ionizable lipids for the delivery of mRNA and pDNA. Their comparative study showed a higher percentage of transfected cells in mRNA formulation than for particles containing pDNA, especially in human retinal pigment epithelial cells . Nonetheless, pDNA delivery resulted in greater protein production per cell in the mentioned cell line. Among the tested lipid formulations, SLNs containing only 1,2-dioleoyl-3-trimethylammonium-propane are considered the most promising for TNAs delivery. Other synthesis methods were used by Wang et al. [29] , who have created aerosolizable dry powder of lipid nanoparticles by thin-film freeze-drying (TFFD), spray drying, and conventional shelf freeze-drying. The researchers comparatively evaluated the obtained powders and tested the feasibility of engineering SLNs using the TFFD method, concluding that this synthesis strategy leads to better aerosol performance properties than the powders obtained otherwise. However, some of the newest approaches for synthesizing LNPs are based on the direct mix of the organic phase (containing the lipids) with the aqueous phase (containing the TNA) using a microfluidic device [32] . Microfluidics represents a robust, scalable, and reproducible synthesis method [33] . This strategy has several advantages compared to conventional techniques as it allows the strict and easy control of flow rates, rapid mixing of the phases, and decreased synthesis time, resulting in nanoparticles with a small size, high monodispersity, and high encapsulation efficiency [28, 34] . For instance, Bailet-Hytholt et al. [21] have synthesized LNPs encapsulated with mRNA or pDNA by means of a precise microfluidic mixing platform. Their experimental For instance, Gomez-Aguado et al. [27] used the solvent emulsification-evaporation method to develop different solid lipid nanoparticles (SLNs) that combine cationic and ionizable lipids for the delivery of mRNA and pDNA. Their comparative study showed a higher percentage of transfected cells in mRNA formulation than for particles containing pDNA, especially in human retinal pigment epithelial cells . Nonetheless, pDNA delivery resulted in greater protein production per cell in the mentioned cell line. Among the tested lipid formulations, SLNs containing only 1,2-dioleoyl-3-trimethylammoniumpropane are considered the most promising for TNAs delivery. Other synthesis methods were used by Wang et al. [29] , who have created aerosolizable dry powder of lipid nanoparticles by thin-film freeze-drying (TFFD), spray drying, and conventional shelf freeze-drying. The researchers comparatively evaluated the obtained powders and tested the feasibility of engineering SLNs using the TFFD method, concluding that this synthesis strategy leads to better aerosol performance properties than the powders obtained otherwise. However, some of the newest approaches for synthesizing LNPs are based on the direct mix of the organic phase (containing the lipids) with the aqueous phase (containing the TNA) using a microfluidic device [32] . Microfluidics represents a robust, scalable, and reproducible synthesis method [33] . This strategy has several advantages compared to conventional techniques as it allows the strict and easy control of flow rates, rapid mixing of the phases, and decreased synthesis time, resulting in nanoparticles with a small size, high monodispersity, and high encapsulation efficiency [28, 34] . For instance, Bailet-Hytholt et al. [21] have synthesized LNPs encapsulated with mRNA or pDNA by means of a precise microfluidic mixing platform. Their experimental setup allowed the self-assembly of nanoparticles under laminar flow, benefiting from advantages such as reproducibility, speed, and low volume screening. Microfluidic methods were also employed by Roces et al. [33] , who have prepared PolyA, ssDNA, and mRNA encapsulated LNPs in a Y-shape staggered herringbone micromixer ( Figure 3 ). In this manner, the researchers obtained a consistent range of particle sizes, with dimen-setup allowed the self-assembly of nanoparticles under laminar flow, benefiting from advantages such as reproducibility, speed, and low volume screening. Microfluidic methods were also employed by Roces et al. [33] , who have prepared PolyA, ssDNA, and mRNA encapsulated LNPs in a Y-shape staggered herringbone micromixer ( Figure 3 ). In this manner, the researchers obtained a consistent range of particle sizes, with dimensions below 100 nm, narrow size distribution, spherical shape, good stability, and high encapsulation efficiencies. In what concerns their applicability, numerous lipid-based TNA delivery platforms have been recently constructed as potent novel platforms for cancer immunotherapies [35] . In particular, the use of mRNA formulations for different types of solid tumors and hematological malignancies is currently examined by various studies and even clinical trials [28] . Targeted LNPs can deliver RNA-based therapeutics to leukocytes to allow the precise and modular manipulation of gene expression, thus being a highly promising approach for many immune-related disorders, such as cancer, autoimmunity, and susceptibility to infectious diseases [36] . TNAs can also be employed in formulations for the treatment and prevention of cardiovascular diseases [37, 38] . Clinical trials have investigated ASOs for lowering low-density lipoprotein cholesterol (LDL-C) [39] , lowering transthyretin (TTR) blood levels [40] [41] [42] , reducing atrial fibrillation burden [43] , reducing serum lipoprotein (a) levels [44] , and preventing neovascular glaucoma [45] . mRNA has also been evaluated for cardiovascular conditions, with several LNP-based formulations being tested for enhancing cardiac function and regeneration [46] , reducing LDL-C levels [47] , and treating endotheliopathy associated with vascular senescence [48, 49] . Similarly, siRNA lipid-based formulations have been clinically tested for TTR-mediated amyloidosis [50] and hypercholesterolemia [51] . Another highly researched application of LNPs is for the development of COVID-19 vaccines, out of which several formulations have already entered clinical use for mRNA delivery [16, [52] [53] [54] [55] . Generally, these vaccines work on the principle of encoding the spike glycoprotein of SARS-CoV-2 ( Figure 4 ) and directing the immune system against these antigens [56, 57] . Clinical trials demonstrated the efficacy of LNP-mRNA formulations and an acceptable safety profile, leading to their approval for mass immunization [58, 59] . In what concerns their applicability, numerous lipid-based TNA delivery platforms have been recently constructed as potent novel platforms for cancer immunotherapies [35] . In particular, the use of mRNA formulations for different types of solid tumors and hematological malignancies is currently examined by various studies and even clinical trials [28] . Targeted LNPs can deliver RNA-based therapeutics to leukocytes to allow the precise and modular manipulation of gene expression, thus being a highly promising approach for many immune-related disorders, such as cancer, autoimmunity, and susceptibility to infectious diseases [36] . TNAs can also be employed in formulations for the treatment and prevention of cardiovascular diseases [37, 38] . Clinical trials have investigated ASOs for lowering low-density lipoprotein cholesterol (LDL-C) [39] , lowering transthyretin (TTR) blood levels [40] [41] [42] , reducing atrial fibrillation burden [43] , reducing serum lipoprotein (a) levels [44] , and preventing neovascular glaucoma [45] . mRNA has also been evaluated for cardiovascular conditions, with several LNP-based formulations being tested for enhancing cardiac function and regeneration [46] , reducing LDL-C levels [47] , and treating endotheliopathy associated with vascular senescence [48, 49] . Similarly, siRNA lipid-based formulations have been clinically tested for TTR-mediated amyloidosis [50] and hypercholesterolemia [51] . Another highly researched application of LNPs is for the development of COVID-19 vaccines, out of which several formulations have already entered clinical use for mRNA delivery [16, [52] [53] [54] [55] . Generally, these vaccines work on the principle of encoding the spike glycoprotein of SARS-CoV-2 ( Figure 4 ) and directing the immune system against these antigens [56, 57] . Clinical trials demonstrated the efficacy of LNP-mRNA formulations and an acceptable safety profile, leading to their approval for mass immunization [58, 59] . COVID-19 vaccines are the most known current examples that make use of LNPs encapsulated with TNA, but this approach can be used for other infectious diseases as well [37, [61] [62] [63] [64] [65] [66] [67] . TNA-LNP formulations have been evaluated against Zika virus [68] , influenza [69, 70] , cytomegalovirus [71, 72] , chikungunya virus [73] , hepatitis B [74] [75] [76] , hepatitis C [77] [78] [79] , human immunodeficiency virus (HIV) [80, 81] , and genital herpes [82] . The development of nonviral platforms for prenatal TNA delivery has recently emerged among the scientific research hot topics as a strategy to treat diseases before the onset of irreversible pathology and a non-invasive alternative to difficult-to-perform surgeries. What is more, the small size of a fetus compared to a postnatal recipient is a key factor for maximizing the delivery vector titer per weight of the recipient, thus, facilitating gene transduction [37, 83] . In this regard, Riley et al. [84] have recently developed a library of ionizable LNPs for in utero mRNA delivery to mouse fetuses. Their LNPs successfully accumulated within fetal livers, lungs, and intestines, with higher therapeutic efficacy and safety than reference delivery systems (i.e., DLin-MC3-DMA and jetPEI), being promising candidates for protein replacement and gene editing platforms. A series of examples of potential applications of lipid-based TNA delivery systems have been synthesized in Table 1 to summarize the above discussion and emphasize the versatility of such formulations. COVID-19 vaccines are the most known current examples that make use of LNPs encapsulated with TNA, but this approach can be used for other infectious diseases as well [37, [61] [62] [63] [64] [65] [66] [67] . TNA-LNP formulations have been evaluated against Zika virus [68] , influenza [69, 70] , cytomegalovirus [71, 72] , chikungunya virus [73] , hepatitis B [74] [75] [76] , hepatitis C [77] [78] [79] , human immunodeficiency virus (HIV) [80, 81] , and genital herpes [82] . The development of nonviral platforms for prenatal TNA delivery has recently emerged among the scientific research hot topics as a strategy to treat diseases before the onset of irreversible pathology and a non-invasive alternative to difficult-to-perform surgeries. What is more, the small size of a fetus compared to a postnatal recipient is a key factor for maximizing the delivery vector titer per weight of the recipient, thus, facilitating gene transduction [37, 83] . In this regard, Riley et al. [84] have recently developed a library of ionizable LNPs for in utero mRNA delivery to mouse fetuses. Their LNPs successfully accumulated within fetal livers, lungs, and intestines, with higher therapeutic efficacy and safety than reference delivery systems (i.e., DLin-MC3-DMA and jetPEI), being promising candidates for protein replacement and gene editing platforms. A series of examples of potential applications of lipid-based TNA delivery systems have been synthesized in Table 1 to summarize the above discussion and emphasize the versatility of such formulations. Cationic polymers have attracted interest for the development of innovative TNA carriers. The main reasoning is that they form electrostatic nanocomplexes with nucleic acids, which are highly negative, to facilitate their uptake by targeted cells. Alternatively, other hydrophobic polymers can physically entrap TNAs within nanoparticles [4] . The first polymer tested as a vehicle for in vitro-transcribed mRNA was diethylaminoethyl (DEAE) dextran. However, after it was proven that lipid-mediated mRNA transfection is 100 to 1000 times more efficient than DEAE-dextran, the evolution of polymeric carriers has been stalled, the attention shifting towards creating perpetually improved lipid-based nanosystems [111] . Nonetheless, after some time, research started being oriented towards developing natural and synthetic polymer-based nanosystems for TNAs delivery as an alternative for cancer treatments and non-viral vaccine formulations. Polymers such as hyaluronic acid [94, [112] [113] [114] , chitosan [94, 113] , DEAE dextran [111] , poly-L-lysine (PLL) [94] , polybeta-amino-esters (PBAE) [111] , polyethylenimine (PEI) [94, 111] , dimethylaminoethyl methacrylate (DEAMA) [111] , poly(ethylene glycol) methacrylate (PEGMA) [111] , and DEAEMA-co-n-butyl methacrylate [111] represent promising candidates for various TNAs delivery platforms. Another interesting possibility is to combine two or more polymers in the same delivery system. For instance, Lü et al. [115] have developed antibody (Ab)-conjugated lactic-co-glycolic-PEI nanoparticles (LGA-PEI NPs) for the active-targeting delivery of TNAs. The research group obtained promising results for pancreatic cancer cells delivery both in vitro and in vivo, concluding that the synthesized carriers can be employed for other types of cancers as well if other specific biomarkers are targeted. Polymers have also been tested for microneedle-based TNA delivery [111] . Koh et al. [116] have fabricated an mRNA-loaded dissolving microneedle patch from polyvinylpyrrolidone (PVP) for cutaneous TNA administration. This RNA-patch can mediate in vivo transgene expression for up to 72 h, the transfection efficiency and kinetics being comparable to subcutaneous injection. Moreover, this innovative delivery system induced higher cellular and humoral immune responses than subcutaneous injection. A similar administration strategy was used by Pan et al. [117] , who have delivered signal transducer and activity transcription 3 (STAT3)-targeting PEI-encapsulated siRNA through dextran-hyaluronic acid dissolving microneedles. The researchers obtained promising results as the microneedles effectively penetrated and rapidly dissolved into the skin. In addition, the delivered complex successfully suppressed the development of melanoma by silencing the STAT3 gene. To briefly summarize the current research progress, several examples of polymerbased TNA delivery systems and their applications have been gathered in Table 2 . Although various types of polymers and copolymers have been tested for TNAs delivery, the poorly understood correlation between their structure and their biological response hinders their development. Moreover, the polydispersity and difficulty in metabolizing large molecular weight polymers make them less appealing than LNPs. Their clinical application is also impeded by potential toxicity, colloidal instability, and relatively poor transfection efficiency [64, 111] . Therefore, more research is required for understanding the influence of polymers' chemical structure on their biological activity and optimally modulating their properties to overcome current challenges. Hybrid delivery systems have recently appeared as an alternative solution for overcoming the limitations of each individual lipid or polymer component. Specifically, the adverse effects of ionizable lipids (e.g., potential immune activation, cytotoxicity) are commonly mediated by shielding the LNPs with polyethylene glycol (PEG) [11] . For example, Sanghani et al. [123] have PEGylated LNPs made of pH-sensitive cationic lipid CL4H6 to safely and efficiently deliver myocardin-related transcription factor B (MRTF-B) siRNA into human conjunctival fibroblasts. A similar hybrid approach on TNA delivery was taken by Scmendel et al. [20] , who have developed folate-containing lipoconjugates with PEG spacers incorporated into a liposome. These delivery systems exhibited higher transfection efficiency compared to non-targeted liposomal formulations and the commercial agent Lipofectamine 2000. Improved transfection efficiency was also obtained using the hybrid nanoparticles created by Siewert et al. [124] . The researchers have developed vehicles for mRNA delivery using different proportions of the cationic lipid DOTAP and the cationic biopolymer protamine, reporting significantly increased transfection in comparison to lipid/mRNA and polymer/mRNA particles alone. Another mRNA hybrid carrier was created by Xiong et al. [125] . This research group developed theranostic dendrimer-based LNPs containing PEGylated BODIPY dyes that combine mRNA delivery and NIR imaging, holding great promise for cancer's simultaneous detection and treatment. Zhou et al. [126] have synthesized a series of linear-dendritic PEG lipids (PEG-GnCm) to investigate the effect of modulating their hydrophobic domain for siRNA delivery as the surface component of dendrimer lipid-based nanoparticles (DLNPs). The researchers used different lipid alkyl lengths (C8, C12, C16) and different dendrimer generations (G1, G2, G3), creating vehicles with different physical properties and anchoring potential. These alterations did not affect particle size, RNA encapsulation, and stability but had a huge impact on delivery efficacy. PEG-G1C8, PEG-G1C12, PEG-G1C16, and PEG-G2C8 could effectively deliver siRNA in vitro and in vivo; however, all the other tested formulations lost their delivery ability, as the escape of DLNPs from endosomes at early cell incubation times was affected. Furthermore, by tailoring the surface charge of LNPs, they can be endowed with targeting ability. According to the comparative study performed by Gabal et al. [127] , anionic nanostructured lipid carriers exhibited 1.2 times higher targeting efficiency in the brain than their cationic counterparts. Thus, such anionic particles hold promise as carriers for brain disorders therapeutics. Nonetheless, anionic formulations have not faced the same development because of difficulties encountered in nucleic acid packaging and poor transfection efficiency. To overcome these challenges, Tagalakis et al. [128] have used cationic targeting peptides as a bridge between the PEGylated anionic liposomes and the pDNA freight. The newly developed structures demonstrated improved tissue penetration, enhanced dispersal, and more widespread cellular transfection than cationic systems. Similar anionic targeting hybrid nanocarriers have also shown promising results for siRNA delivery to neuroblastoma tumors with reduced systemic and cellular toxicity [129] . Another polymer that can be used in combination with LNPs is poly(lactic-co-glycolic acid) (PLGA). In this respect, Yang et al. [130] have developed a PLGA-LNP hybrid delivery system loaded with CRISPR/Cas9 plasmids targeting the MGMT gene and modified with the cRGD peptide. This system was constructed to open the blood-brain barrier (BBB) and ensure targeted gene delivery in vivo under focused ultrasound (FUS) irradiation. The obtained results emphasized a synergic targeting ability of the physically site-specific characteristics of FUS and the biologically active targeting ability of cRGD peptide, recommending this innovative carrier as a candidate for central nervous system TNA delivery. A recently approached strategy for designing performant hybrid carriers is the creation of lipopolyplexes (LPPs), complexes combining nucleic acids with lipids and polymers ( Figure 5 ). Such structures are promising delivery systems for gene therapy, especially due to their compositional, physical, and functional versatility [131] [132] [133] . For instance, Wang et al. [134] have synthesized a tumor-selective LPP consisting of a PEI/p21-saRNA-322 core and a hyaluronan-modulated lipid shell. The system was tested against colorectal cancer, and it was reported that it accumulated preferentially at the tumor site, leading to superior antitumor efficacy in vitro and in vivo. Alternatively, Shah et al. [135] have proposed the incorporation of ultrasound contrast agents in the liposomal cavity, followed by polyplexes addition. Thus, the scientists obtained ultrasound-activated LPPs that promote cancer cell uptake, elevate transfection efficiency, and reduce carrier cytotoxicity. Pharmaceutics 2021, 13, x FOR PEER REVIEW 16 of 27 delivery system loaded with CRISPR/Cas9 plasmids targeting the MGMT gene and modified with the cRGD peptide. This system was constructed to open the blood-brain barrier (BBB) and ensure targeted gene delivery in vivo under focused ultrasound (FUS) irradiation. The obtained results emphasized a synergic targeting ability of the physically sitespecific characteristics of FUS and the biologically active targeting ability of cRGD peptide, recommending this innovative carrier as a candidate for central nervous system TNA delivery. A recently approached strategy for designing performant hybrid carriers is the creation of lipopolyplexes (LPPs), complexes combining nucleic acids with lipids and polymers ( Figure 5 ). Such structures are promising delivery systems for gene therapy, especially due to their compositional, physical, and functional versatility [131] [132] [133] . For instance, Wang et al. [134] have synthesized a tumor-selective LPP consisting of a PEI/p21-saRNA-322 core and a hyaluronan-modulated lipid shell. The system was tested against colorectal cancer, and it was reported that it accumulated preferentially at the tumor site, leading to superior antitumor efficacy in vitro and in vivo. Alternatively, Shah et al. [135] have proposed the incorporation of ultrasound contrast agents in the liposomal cavity, followed by polyplexes addition. Thus, the scientists obtained ultrasound-activated LPPs that promote cancer cell uptake, elevate transfection efficiency, and reduce carrier cytotoxicity. One more emerging delivery possibility is TNA transport via lipodendriplexes which are complex structures formed by non-covalent hybridization of dendriplexes with the liposomal membrane. In this respect, Tariq et al. [136] have incorporated pDNA-PA-MAM-based dendriplexes into an optimized liposomal formulation ( Figure 6 ). The researchers reported significantly improved pDNA transfection, lower LDH release, lower ROS generation, higher cellular protein content, and higher cell viability compared to dendriplexes without the lipid components. Thus, these new carriers can be considered promising candidates for efficient and biocompatible gene delivery systems. One more emerging delivery possibility is TNA transport via lipodendriplexes which are complex structures formed by non-covalent hybridization of dendriplexes with the liposomal membrane. In this respect, Tariq et al. [136] have incorporated pDNA-PAMAMbased dendriplexes into an optimized liposomal formulation ( Figure 6 ). The researchers reported significantly improved pDNA transfection, lower LDH release, lower ROS generation, higher cellular protein content, and higher cell viability compared to dendriplexes without the lipid components. Thus, these new carriers can be considered promising candidates for efficient and biocompatible gene delivery systems. To summarize the current status of lipid polymer-hybrid-based TNA carriers, Table 3 presents several examples of such delivery systems together with their potential applications. Pharmaceutics 2021, 13, x FOR PEER REVIEW 17 of 27 To summarize the current status of lipid polymer-hybrid-based TNA carriers, Table 3 presents several examples of such delivery systems together with their potential applications. LNPs are undeniably promising innovative nonviral vectors for gene delivery. Nonetheless, several challenges still exist, limiting their potential. One of the main unresolved issues is represented by the poor endosomal escape after LNP cell entry. Attempting to understand this phenomenon, Herrera et al. [140] have created a highly sensitive and robust galectin 8-GFP (Gal8-GFP) cell reporter system to visualize the endosomal escape capabilities of LNP-encapsulated mRNA. This sensor system allows the rapid and efficient distinction of endosomal membrane integrity as an indicator of cytosolic availability of mRNA. Moreover, it helped the researchers identify differences in endosomal escape capabilities elicited by the varying sterol composition of mRNA LNP-based delivery systems. Alternatively, Mihaila et al. [141] propose the optimization of siRNA LNP-mediated delivery by use of an ordinary differential equation (ODE)-based model. By means of mathematical modeling, the researchers designed and validated a predictive model that can compare the relative kinetics of different classes of LNPs towards choosing the best option. Another problem associated with LNPs is that their intravenous administration results in liver accumulation where the reticuloendothelial system takes them up. To avoid this situation, Saunders et al. [142] propose the administration of a liposome (i.e., Nanoprimer) that can temporarily occupy liver cells as a pretreatment before LNPs delivery. The researchers obtained promising results as the Nanoprimer improved the bioavailability of tested RNA-encapsulated LNPs, increased protein production, and enhanced FVII silencing. One more aspect that must be considered regarding lipid and polymer-based TNA delivery systems is the development of a biomolecular corona around these nanoparticles (Figure 7) . This "crown" is formed by electrolytes, proteins, and lipids adsorbed on nanomaterials' surfaces when in contact with a biological environment. As the association process is almost irreversible, the biomolecular corona defines the biological identity of the nanosystem, impacting in vivo characteristics, such as circulation time, biodistribution, uptake kinetics, macrophage recognition, release profile, or targeting [143] [144] [145] . LNPs are undeniably promising innovative nonviral vectors for gene delivery. Nonetheless, several challenges still exist, limiting their potential. One of the main unresolved issues is represented by the poor endosomal escape after LNP cell entry. Attempting to understand this phenomenon, Herrera et al. [140] have created a highly sensitive and robust galectin 8-GFP (Gal8-GFP) cell reporter system to visualize the endosomal escape capabilities of LNP-encapsulated mRNA. This sensor system allows the rapid and efficient distinction of endosomal membrane integrity as an indicator of cytosolic availability of mRNA. Moreover, it helped the researchers identify differences in endosomal escape capabilities elicited by the varying sterol composition of mRNA LNP-based delivery systems. Alternatively, Mihaila et al. [141] propose the optimization of siRNA LNP-mediated delivery by use of an ordinary differential equation (ODE)-based model. By means of mathematical modeling, the researchers designed and validated a predictive model that can compare the relative kinetics of different classes of LNPs towards choosing the best option. Another problem associated with LNPs is that their intravenous administration results in liver accumulation where the reticuloendothelial system takes them up. To avoid this situation, Saunders et al. [142] propose the administration of a liposome (i.e., Nanoprimer) that can temporarily occupy liver cells as a pretreatment before LNPs delivery. The researchers obtained promising results as the Nanoprimer improved the bioavailability of tested RNA-encapsulated LNPs, increased protein production, and enhanced FVII silencing. One more aspect that must be considered regarding lipid and polymer-based TNA delivery systems is the development of a biomolecular corona around these nanoparticles (Figure 7) . This "crown" is formed by electrolytes, proteins, and lipids adsorbed on nanomaterials' surfaces when in contact with a biological environment. As the association process is almost irreversible, the biomolecular corona defines the biological identity of the nanosystem, impacting in vivo characteristics, such as circulation time, biodistribution, uptake kinetics, macrophage recognition, release profile, or targeting [143] [144] [145] . Thus, when moving from in vitro models to in vivo studies or clinical trials, it may be expected to encounter a weaker delivery efficiency and therapeutic effect of carried nucleic acids. To overcome this issue, Yang et al. [147] have proposed the design of a corona made from cyclic RGDyK peptide-modified bovine serum albumin to be used as a precoat on a redox-responsive chitosan-based nanocarrier for siRNA delivery. The synthesized corona remained steady around the delivery vehicle, improved the system's stability, biocompatibility, and targeting ability, reduced serum proteins adsorption, increased intracellular uptake, facilitated the lysosomal escape while maintaining the redox-sensitive responsiveness of the nanocarrier. To conclude, TNAs represent a promising therapeutic strategy for a broad range of diseases. Benefiting from tremendous scientific interest in the recent years, numerous LNP-based delivery systems for pDNA, mRNA, siRNA, and other nucleic acids have appeared that can help fight against various cancers, infectious diseases, cardiovascular diseases, and inherited disorders. Several such formulations have reached the clinical trials testing stage or have even been approved for use in the general population in record time, as is the case of LNP-mRNA COVID-19 vaccines. Other TNA delivery possibilities started to emerge as well, including polymer and lipid-polymer hybrid carriers. Nonetheless, these delivery systems are still in their infancy, most of them requiring further thorough research before moving from in vitro and in vivo tests to clinical studies. Overall, the evolution in developing targeted and controlled release vehicles for efficient cellular uptake faces exponentially increasing progress. Given the recent research growth in the field and the precedent it has been created with the approval of the COVID-19 vaccines, it can be expected that other TNA delivery systems will soon enter the market. Approaches to Modulate the Chronic Wound Environment Using Localized Nucleic Acid Delivery The current landscape of nucleic acid therapeutics Lipid nanoparticles as delivery systems for RNA-based vaccines Polymeric nucleic acid delivery for immunoengineering Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines Paving the Road for RNA Therapeutics Extracellular Vesicle-Based Nucleic Acid Delivery: Current Advances and Future Perspectives in Cancer Therapeutic Strategies Nanoscale platforms for messenger RNA delivery A new developing class of gene delivery: Messenger RNA-based therapeutics Smart Nanocarriers for the Delivery of Nucleic Acid-Based Therapeutics: A Comprehensive Review Lipid nanoparticles for nucleic acid delivery: Current perspectives Advances in vaccine delivery systems against viral infectious diseases A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles Non-viral COVID-19 vaccine delivery systems Lipid nanoparticles for mRNA delivery Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: Impact on translational nanomedicine Lipid nanocarriers for microRNA delivery Effects of spacers within a series of novel folate-containing lipoconjugates on the targeted delivery of nucleic acids Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform Formulation and development of hesperidin loaded solid lipid nanoparticles for diabetes Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement Strategies for Successful Formulation Development of Lipid-Based RNA Delivery and Vaccines New methods for lipid nanoparticles preparation Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA. Molecules Advances in lipid nanoparticles for mRNA-based cancer immunotherapy Aerosolizable siRNAencapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery Exosomes and Lipid Nanoparticles-the Future of Targeted Drug Delivery. Bachelor's Degree Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics Use of nanoparticles in delivery of nucleic acids for melanoma treatment Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes The nano delivery systems and applications of mRNA mRNA-Based Protein Replacement Therapy for the Heart Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis (MICA) The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients Patients With TTR Amyloid Cardiomyopathy Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation (ASET) Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA). Available online Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG (STRONG) Abstract 18088: Myocardial Delivery of Lipidoid Nanoparticle mRNA Designed for Tailored Expression of Cardiogenic Factors Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets Telomerase mRNA Reverses Senescence in Progeria Cells mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration ALN-TTR02) in Transthyretin (TTR) Amyloidosis. Available online Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (ORION-1) Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque Chemical Structure, Therapeutics, Drugs and Vaccines Contribution of nanotechnology in the fight against COVID-19 Nucleic Acid-Based Technologies Targeting Coronaviruses Variety of spike protein in covid-19 mutation: Stability, effectiveness and outbreak rate as a target for vaccine and therapeutic development Therapeutic Strategies of COVID-19: From Natural Compounds to Vaccine Trials Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting Nanomaterial Delivery Systems for mRNA Vaccines The find of COVID-19 vaccine: Challenges and opportunities mRNA vaccines for infectious diseases: Principles, delivery and clinical translation Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility Messenger RNA-Based Vaccines against Infectious Diseases A Review on COVID-19: Origin, Spread, Symptoms, Treatment, and Prevention Evaluation of Coronavirus Families & Covid-19 Proteins: Molecular Modeling Study Properties and Reactivities of Niclosamide in Different Media, a Potential Antiviral to Treatment of COVID-19 by Using DFT Calculations and Molecular Docking Immunogenicity of mRNA-1325 in Healthy Adult Subjects Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Immunogenicity of VAL-181388 in Healthy Subjects siRNA drug development against hepatitis B virus infection ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates An HSV-2 nucleosidemodified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection Delivery technologies for in utero gene therapy Ionizable lipid nanoparticles for in utero mRNA delivery Lipid-Modified Aminoglycosides for mRNA Delivery to the Liver Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) (Atu027-I-02) Study With Atu027 in Patients With Advanced Solid Cancer Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH). Available online EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Dose Escalation Study of DCR-MYC in Patients with Solid Tumors, Multiple Myeloma, or Lymphoma Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination with Durvalumab for Participants With Advanced Malignancies A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors Results of a Phase I Trial of SGT-53: A Systemically Administered, Tumor-Targeting Immunoliposome Nanocomplex Incorporating a Plasmid Encoding wtp53 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants with Immunological Failure Initial to Vaccination A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above COVID-19 Vaccination of Immunodeficient Persons (COVAXID) Third Dose of mRNA Vaccination to Boost COVID-19 Immunity Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults Opportunities and challenges in the delivery of mRNA-based vaccines Chapter 12-Hyaluronic Acid as an Emerging Technology Platform for Silencing RNA Delivery Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives An Unexpected Role of Hyaluronic Acid in Trafficking siRNA Across the Cellular Barrier: The First Biomimetic, Anionic, Non-Viral Transfection Method Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch) Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose Synthetic Chemically Modified mRNA-Based Delivery of Cytoprotective Factor Promotes Early Cardiomyocyte Survival Post-Acute Myocardial Infarction Safety study of CALAA-01 to treat solid tumor cancers A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT) Novel PEGylated lipid nanoparticles have a high encapsulation efficiency and effectively deliver MRTF-B siRNA in conjunctival fibroblasts Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo Hydrophobic Domain Structure of Linear-Dendritic Poly(ethylene glycol) Lipids Affects RNA Delivery of Lipid Nanoparticles Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine Abalde-Cela, S. In Vitro Evaluation of Lipopolyplexes for Gene Transfection: Comparing 2D, 3D and Microdroplet-Enabled Cell Culture Click-Shielded and Targeted Lipopolyplexes Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine Development and Characterization of Ultrasound Activated Lipopolyplexes for Enhanced Transfection by Low Frequency Ultrasound in In Vitro Tumor Model Lipodendriplexes mediated enhanced gene delivery: A cellular to pre-clinical investigation Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles Internalisation and Biological Activity of Nucleic Acids Delivering Cell-Penetrating Peptide Nanoparticles Is Controlled by the Biomolecular Corona Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications Protein corona precoating on redox-responsive chitosan-based nano-carriers for improving the therapeutic effect of nucleic acid drugs The present work was possible due to the project "Excelent , a academică s , i valori antreprenoriale-sistem de burse pentru asigurarea oportunităt , ilor de formare s , i dezvoltare a competent , elor antreprenoriale ale doctoranzilor s , i postdoctoranzilor"-ANTREPRENORDOC (36355/23.05.2019 POCU/380/6/13). The authors declare no conflict of interest.